These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18624677)

  • 1. Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms.
    Argikar UA; Iwuchukwu OF; Nagar S
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):879-94. PubMed ID: 18624677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.
    Nagar S; Remmel RP
    Oncogene; 2006 Mar; 25(11):1659-72. PubMed ID: 16550166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
    Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
    Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
    Nagar S; Blanchard RL
    Drug Metab Rev; 2006; 38(3):393-409. PubMed ID: 16877259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT genomic diversity: beyond gene duplication.
    Guillemette C; Lévesque E; Harvey M; Bellemare J; Menard V
    Drug Metab Rev; 2010 Feb; 42(1):24-44. PubMed ID: 19857043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.
    Miners JO; McKinnon RA; Mackenzie PI
    Toxicology; 2002 Dec; 181-182():453-6. PubMed ID: 12505351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Phenotypically Poor Metabolizer Individual Donor Human Liver Microsomes To Identify Selective Substrates of UGT2B10.
    Milani N; Qiu N; Molitor B; Badée J; Cruciani G; Fowler S
    Drug Metab Dispos; 2020 Mar; 48(3):176-186. PubMed ID: 31839590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk.
    Hu DG; Mackenzie PI; McKinnon RA; Meech R
    Drug Metab Rev; 2016; 48(1):47-69. PubMed ID: 26828111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Review on gene polymorphisms of UDP-glucuronosyltransferases and genetic susceptibility of cancer].
    Wang Y; Zheng Y
    Wei Sheng Yan Jiu; 2008 Sep; 37(5):629-32. PubMed ID: 19069670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of cloned and expressed human liver UDP-glucuronosyltransferases for analysis of drug glucuronide formation and assessment of drug toxicity.
    Burchell B; Ebner T; Baird S; Bin Senafi S; Clarke D; Brierley C; Sutherland L
    Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):19-23. PubMed ID: 7698078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism.
    Zhang D; Zhang D; Cui D; Gambardella J; Ma L; Barros A; Wang L; Fu Y; Rahematpura S; Nielsen J; Donegan M; Zhang H; Humphreys WG
    Drug Metab Dispos; 2007 Dec; 35(12):2270-80. PubMed ID: 17898154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes.
    Rouguieg K; Picard N; Sauvage FL; Gaulier JM; Marquet P
    Drug Metab Dispos; 2010 Jan; 38(1):40-5. PubMed ID: 19841060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UDP-glucuronosyltransferases and clinical drug-drug interactions.
    Kiang TK; Ensom MH; Chang TK
    Pharmacol Ther; 2005 Apr; 106(1):97-132. PubMed ID: 15781124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucuronidation in humans. Pharmacogenetic and developmental aspects.
    de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
    Clin Pharmacokinet; 1999 Jun; 36(6):439-52. PubMed ID: 10427468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors.
    Kasteel EEJ; Darney K; Kramer NI; Dorne JLCM; Lautz LS
    Arch Toxicol; 2020 Aug; 94(8):2637-2661. PubMed ID: 32415340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation.
    Burchell B
    Am J Pharmacogenomics; 2003; 3(1):37-52. PubMed ID: 12562215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.
    Guillemette C; Lévesque É; Rouleau M
    Clin Pharmacol Ther; 2014 Sep; 96(3):324-39. PubMed ID: 24922307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UDP-glucuronosyltransferases.
    King CD; Rios GR; Green MD; Tephly TR
    Curr Drug Metab; 2000 Sep; 1(2):143-61. PubMed ID: 11465080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases.
    Court MH
    Methods Enzymol; 2005; 400():104-16. PubMed ID: 16399346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the zebrafish Ugt repertoire reveals a new class of drug-metabolizing UDP glucuronosyltransferases.
    Wang Y; Huang H; Wu Q
    Mol Pharmacol; 2014 Jul; 86(1):62-75. PubMed ID: 24728488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.